Recent results suggest that there are likely to be many true association signals in large psychiatric genome-wide association study (GWAS) data sets. 1 The big challenge of the field is the identification of these risk genes of small effect. We attempt to address this issue by using Psychiatric Genetics Consortium (PGC) GWAS data sets [2] [3] [4] to test whether functional variants from the GWAS are significantly enriched in low P-values when compared with the remainder of the GWAS data set.
We hypothesized that as functional single-nucleotide polymorphisms (SNPs) can directly affect gene expression and function, they are likely to significantly have an impact on disease risk. Therefore, functional SNPs are more likely to have true association signals. To test this hypothesis, we used genomic control-adjusted statistics 5 from PGC schizophrenia, 3 bipolar disorder 4 and major depression disorder 2 GWAS data sets to investigate SNPs that (i) affect transcription factor-binding sites in the promoter regions (promoter SNPs), (ii) change gene expression via microRNA binding (microRNA SNPs) and DNA methylation (methylation SNPs), and (iii) correlate with gene expression (eQTL (expression quantitative trait loci) SNPs) in different brain regions.
The experimentally validated promoter SNPs were obtained from dbQSNP (http://qsnp.gen.kyushu-u.ac.jp/), whereas the microRNA, methylation and eQTL SNPs were obtained from the literature. 6, 7 We used all SNPs deemed statistically significant by the original studies (Supplementary Table S1 ). We extracted the association P-values for these functional SNPs from the PGC GWAS data sets, and tested if these SNPs were more enriched in association signals than the entire GWAS using the Simes and sum of squares tests (SST) (see Supplementary Methods). To account for the linkage disequilibrium amongst selected SNPs, the statistical significance of SST was assessed via 50 000 permutations based on the linkage disequilibrium patterns of the 288 European subjects sequenced by the 1000 Genomes Project. 8 The results are summarized in Table 1 . When applying SST, 6 of the 10 groups of SNPs (promoter SNPs, eQTL SNPs in the frontal cortex and cerebellum, methylation SNPs in the temporal cortex, pons and frontal cortex) showed significant enrichment above GWAS background for association signals for schizophrenia. Promoter SNPs were also significantly enriched in association with bipolar disorder, and showed a trend in major depression. No significant enrichments were detected by the Simes test (Supplementary  Table S2 ).
Intuitively, the Simes test is useful to detect SNP sets having few strong signals, and SST is valuable at detecting SNP sets having many signals of small effect. Thus, our results suggest that there are no SNPs showing stronger associations than that observed in the GWASs. In contrast, SST results indicate that many promoter, eQTL and methylation SNPs seem to have a modest association with both schizophrenia and bipolar disorder. As the tested functional groups overlap, we conducted post hoc analyses for the unique SNPs amongst the significant groups. There were 11 868 unique SNPs amongst the methylation SNP groups, and they were significantly enriched for schizophrenia signals (Po0.0001). The 4178 unique eQTL SNPs were enriched for similar signals as well (P ¼ 0.0006). There were 127 and 49 shared SNPs between the promoter/methylation and between the promoter/eQTL groups (Supplementary Table S1 ), and both shared SNPs were enriched in schizophrenia association signals (P ¼ 0.0014 and 0.07, respectively). A pathway analysis of these shared SNPs indicated that they are involved in DNA replication and repair, cell cycle, cellular development and proliferation, system development and function, neurological disease and immune response (Supplementary  Tables S3 and S4) .
In this study, we found that functional SNPs are more enriched in association signals than the remainder of the PGC GWAS data. The most significant enrichment was found in promoters for schizophrenia and bipolar disorder, and eQTL and methylation SNPs for schizophrenia. We noticed a trend for a decrease of enrichment signals across the disorders, a reflection of the power (sample size) of original studies. We also observed that there are differences in association signals across brain regions, supporting the notion that brain dysfunction in schizophrenia may be regionspecific. Overall, our results suggested that for GWAS data sets with reasonable power, systematically selecting and testing functional SNPs may be an effective approach to identify risk genes with small but true effect. This conclusion may be extended to other complex diseases. Autism is a highly heterogeneous neurodevelopmental disorder with impaired language, social communication, and restricted and repetitive interests and behavior. Monogenic developmental brain disorders with autism features such as Rett syndrome, Angelman syndrome, Fragile X syndrome, and others provide important tractable models of relevance to severe autism. In addition to observing autism symptoms in the monogenic condition, if the gene responsible is also significantly misregulated in the brains of people with idiopathic autism, then these data provide substantial independent support for the importance of the gene in autism pathophysiology. Given this logic, we set out to test if there were gene expression changes in postmortem brain tissue from patients with idiopathic autism in the genes of interest that encode the Na þ /H þ exchanger family of proteins, with particular interest in the forms of exchangers localized to endosomes, namely, NHE6 and NHE9. Mutations in the X-linked endosomal Na þ /H þ Exchanger 6 (NHE6, also known as SLC9A6) represent a novel neurogenetic syndrome with variable expressivity. 1 In a systematic, large-scale resequencing screen of X-chromosome coding exons in 4200 pedigrees consistent with X-linked intellectual disability, NHE6 was among the top six most recurrently mutated genes. 2 The 'Christianson syndrome', based on the initial clinical description, reported an association with autistic symptoms as has been reported subsequently. 3, 4 In parallel to the description of autistic symptoms associated with mutations in NHE6, Morrow et al. 5 published mutations in the highly related endosomal protein NHE9 in severe autism with epilepsy. Endosomal processes, such as would be suggested by mutations in NHE6 and NHE9, represent an important cellular mechanism for investigations regarding disorders of cognitive development. Interestingly, of the six top genes implicated in the Tarpey et al.
2 study, two of the genes, NHE6 and AP1S2, are known to be involved in endosomal mechanisms.
We therefore investigated whether the expression of NHE genes, NHE6 and NHE9, were altered in autism cerebral cortex. We did this by renormalizing and analyzing publically available microarray data. Specifically, we first analyzed data from Voineagu et al., 6 which were previously used to compare autism and control cortex (n ¼ 29 of each). We renormalized the data as described in Voineagu et al., 6 except for when we wished to analyze a subset of NHE genes that were excluded from the analysis because of low expression. Among their results, Voineagu et al. 6 reported that synapse-associated genes were downregulated in autism cortex, 6 and we confirmed this result by performing differential gene expression analysis 7 between autism and control cortex (for detailed Methods, please see Supplementary Information). We then performed DAVID functional annotation clustering analysis 8, 9 on the 197 genes with at least 1.3-fold reduction in autism cortex and Po0.05 (after Benjamini-Hochberg adjustment 10 ), which were the differential expression cutoffs described by Voineagu et al. 6 Indeed, the most significant gene set in the top scoring cluster of the DAVID results was the Gene Ontology term 'synapse,' for which 21 genes overlapped with those downregulated in autism cortex (BH-adjusted overlap P-value ¼ 2.2 Â 10 À 7 ). This confirmed that synapse-related genes, such as GABRA1 and CHRM1, were downregulated in autism cortex in the Voineagu et al. 6 data set (Supplementary Tables 1 and 2 for description of the downregulated synapse genes). We next tested whether NHE genes (NHE1-11) were differentially expressed between autism and control cortex using a t-test (Supplementary Table 3 ). Notably, NHE1 and NHE6 were significantly downregulated in autism cortex (P ¼ 0.0030 and 0.0042, respectively) and NHE9 was significantly upregulated (P ¼ 0.00075), yet other NHE genes were not significantly differentially expressed between autism and control cortex (P40.15).
We further hypothesized that changes in these genes were reflective of broader changes in gene expression, such as downregulation of synapse genes. To investigate the functional changes associated with NHE1, NHE6 and NHE9 gene expression, we found Pearson correlation coefficients between each of these genes and the average expression of the 21 synapse-related genes. NHE1 was not significantly correlated with the synapse genes (r ¼ 0.15, P ¼ 0.28), but NHE6 and NHE9 both were strongly correlated with the synapse genes (r ¼ 0.86, P ¼ 4.2 Â 10 À 18 for NHE6; r ¼ À 0.62, P ¼ 2.2 Â 10 À 7 for NHE9-see Figure 1 ). Furthermore, the sub-population of samples with the lowest NHE6 expression was almost entirely autism cases, as was the subpopulation of high NHE9 expression. Additionally, NHE6 and NHE9 were negatively correlated (P ¼ 0.00015), and when NHE6 expression was high, NHE9 was tightly regulated. A similar decrease in NHE9 variability could be seen with high synapse gene expression (Figure 1 ). Thus, a sub-population within autism is not only associated with lower synapse gene expression, but also with lower NHE6 expression and increased and potentially misregulated NHE9 expression. We also studied the correlation of NHE6 and NHE9 with the downregulated synapse gene set during normal brain development. We capitalized on the large mRNA-seq data set from human brain made available by the Allen Brain Institute (http://www.developinghumanbrain.org). We find that NHE6 clusters strongly during development with this synapse gene group (see Supplementary Information). NHE9 expression was far lower embryonically, increased postnatally but did not appreciably cluster with this synapse group in typical brain development (Supplementary Figures 1-3) .
We used two independent microarray data sets for autism and control cerebral cortex to validate both the differential gene expression of NHE6 and NHE9 in autism cases and these genes' associations with synapse genes. The validation data sets were
